modeled as a continuous predictor. To assess potential effect modification, analyses were repeated among strata that were defined by preeclampsia status, maternal age (!35 vs 18e34 years), and infant sex. RESULTS: Abruptio placentae cases were more likely to have preeclampsia, shorter gestational age, and lower infant birthweight. Participants in quartile 2 (score, 12.6e13.8), quartile 3 (score, 13.9e15.0) and quartile 4 (score, !15.1) had a genetic risk score of 1.45-fold (95% confidence interval, 1.04e2.02; P¼.03), a 1.42-fold (95% confidence interval, 1.02e1.98; P¼.04), and a 1.75-fold (95% confidence interval, 1.27e2.42; P¼7.0E-04) higher odds of abruptio placentae, respectively, compared with those in quartile 1 (score,<12.6; P-for trend¼.0003). The risk of abruptio placentae was 1.12-fold (95% confidence interval, 1.05e1.19; P¼3.0Â10 04 ) higher per 1-unit increase in the score. Among women with preeclampsia, those in quartile 4 had a 3.92-fold (95% confidence interval, 1.48e10.36; P¼.01) higher odds of abruptio placentae compared with women in quartile 1. Among normotensive women, women in quartile 4 had a 1.57-fold (95% confidence interval, 1.11e2.21; P¼.01) higher odds of abruptio placentae compared with those in quartile 1 (P-for interaction¼.12). We did not observe differences in associations among strata defined by maternal age or infant sex. CONCLUSION: In this study, we replicated previous findings and provide strong evidence for DNA variants that encode for genes that are involved in mitochondrial biogenesis and oxidative phosphorylation pathways, which confers risk for abruptio placentae. These results shed light on the mechanisms that implicate DNA variants that encode for proteins in mitochondrial function that are responsible for abruptio placentae risk. Therapeutic efforts to reduce risk of abruptio placentae can be enhanced by improved biologic understanding of maternal mitochondrial biogenesis/ oxidative phosphorylation pathways and identification of women who would be at high risk for abruptio placentae.
Key words: abruptio placentae, genome, mitochondria, placenta A bruptio placentae (AP) is an obstetric complication that is characterized by the premature separation of an implanted placenta. AP is a significant cause of global maternal and neonatal death and morbidity. 1 As a complex multifactorial disease, pathophysiologic mechanisms of AP include uteroplacental under perfusion, chronic hypoxemia, placental ischemia, and infarctions. 2e8 The role of genetic factors in AP has garnered increasing attention over the past decade. Previous findings for high recurrence of AP, 9 high prevalence of heritable thrombophilia among women with AP, 10 and aggregation of AP in families of women with an abruption 11 Cite this article as: Workalemahu T, Enquobahrie DA, Bizu Gelaye B, et al. Abruptio placentae risk and genetic variations in mitochondrial biogenesis and oxidative phosphorylation: replication of a candidate gene association study. Am J Obstet Gynecol 2018;219:617.e1-17. 12e14 Particularly, there is evidence that shows the role of perturbations in mitochondrial biogenesis (MB) and oxidative phosphorylation (OP) in the pathogenesis of AP from candidate gene studies. 15, 16 The mitochondria control subjects many critical cell functions, which include the production of cellular energy, adenosine triphosphate, by the coupling of OP to cell respiration.
17e19 Oxidative stressinduced damage to mitochondrial structural elements (eg, lipid membrane) alters mitochondrial gene expression and promotes a deficiency in OP, 20 which results in mitochondrial dysfunction. Hundreds of nuclear DNA genes across the chromosome regulate MB and maintain mitochondrial structure and function by regulating OP.
21
Mitochondrial dysfunction can lead to the impairment of differentiation and invasion of the trophoblast and lead to several obstetric complications that includes AP. 22 Epidemiologic and experimental studies have highlighted the roles of MB/OP genes in pregnancy complications that involve the placenta.
23e26 For instance, PPARG, a master regulator gene of MB, mediates defective placentation that results from oxidized low-density lipoproteins in cytotrophoblasts of villous and extravillous cells. 23 Expression of this gene was shown to be reduced in placentae of women with gestational diabetes mellitus. 25 Another MB gene, NR1H3 (Liver X alpha), 27 which plays a key role in cholesterol metabolism 28 and cell signaling, 29 is important in normal trophoblast invasion during placental implantation. 24, 26 In addition to assessment of genetic variations in the whole population, subgroup analyses can help to identify members of the population whose genetic background makes them more susceptible to disease. 30 However, such analyses are largely nonexistent in the context of MB/OP genetic variations and AP risk.
On the basis of this emerging literature, we previously conducted 2 candidate single nucleotide polymorphism (SNP) studies to investigate variations in MB/OP genes and AP risk 16, 31 increased MB/OP wGRS and AP risk. Similarly, increased MB/OP wGRS that was computed based on placental SNPs that were assessed from the fetal-side was also associated with AP risk in the latter study. 31 In this new study, we conducted a replication candidate gene study to examine SNPs in MB/OP genes and risk of AP in the Placental Abruption Genetic Epidemiology (PAGE) study. Of note, the PAGE study had similar design and study population drawn from the same catchment area as the PAPE study but did not include participants from any of the previously published studies. In addition, we examined the extent to which the association of wGRS with AP risk is modified by known and potential risk factors of AP: preeclampsia, 32 advanced maternal age, 33 and infant sex. 34 These analyses could have important clinical and public health implications by highlighting potential gene-gene or gene-environment interactions, enhancing the biologic understanding of the mechanisms that lead to AP, and facilitating therapeutic efforts to reduce impact of AP. 35 
Materials and Methods

Study settings and study populations
The study was conducted among participants of the PAGE study, a casecontrol study of AP conducted in Lima, Peru. Study participants included women who were admitted for obstetrics services to antepartum wards, emergency room, and labor and delivery wards of participating hospitals between March 2013 and December 2015. Participating hospitals were Instituto Nacional Materno Perinatal, Hospital Edgardo Rebagliati Martins, Hospital San Bartolome, Hospital Hipolito Unanue, Hospital Arzobispo Loayza, Hospital Dos de Mayo, and Hospital Maria Auxiliadora. Participants who were <18 years old, had delivered a multifetal pregnancy, had medical records that were insufficient to determine the presence or absence of AP (described later), and reported taking anticoagulants were excluded from the study. Participants with other diagnoses that were associated with third-trimester AJOG at a Glance Why was this study conducted? We conducted the study to replicate results of a candidate genetic association study that indicated a link between DNA variants that are implicated in mitochondrial biogenesis and oxidative phosphorylation and abruptio placentae.
Key Findings
Genetic risk score calculated with the use of abruptio placentae risk-increasing alleles of genes that is involved in mitochondrial biogenesis and oxidative phosphorylation was associated with abruptio placentae risk; this association was stronger among women with preeclampsia.
What does this add to what is known?
The findings reported herein provide strong evidence for DNA variants encoding for genes that are involved in the mitochondrial biogenesis and oxidative phosphorylation pathways that confer risk for abruptio placentae.
Original Research OBSTETRICS ajog.org bleeding (eg, placenta previa) were also excluded. The total number of participants remained 522 AP cases and 1147 control subjects. The study protocol was approved by the Institutional Review Boards of participating institutions and the Swedish Medical Center, Seattle, WA, where the study was administratively based. All participants provided written informed consent.
Data collection
Study participants were interviewed by trained personnel who used standardized structured questionnaires to collect information on sociodemographic characteristics and risk factors that included maternal age, marital status, employment status during pregnancy, medical history, smoking, and alcohol consumption (both current and a Data were complete except for the following variables: maternal age (7 cases, 12 control subjects), education (9 cases, 6 control subjects), marital status (5 cases, 3 control subjects), employment status (5 cases, 3 control subjects), prepregnancy body mass index (10 cases, 22 control subjects), planned pregnancy (5 cases, 9 control subjects), smoking status (2 cases, 6 control subjects), drug abuse during pregnancy (3 cases, 6 control subjects), preeclampsia status (7 cases, 15 control subjects), vitamin use during pregnancy (7 cases, 19 control subjects), gestational age at delivery (77 cases, 135 control subjects), infant sex (6 cases, 10 control subjects), and infant birthweight (7 cases, 13 control subjects); b Probability values are from Chi-square test/Fisher's exact test for the categoric variables and Student t test for continuous variables; c Data are given as meanAEstandard deviation.
Workalemahu et al. Risk of abruptio placentae is associated with genetic variations in mitochondrial biogenesis and oxidative phosphorylation. Am J Obstet Gynecol 2018.
ajog.org 36 Control subjects were selected randomly from eligible pregnant women who delivered at the same participating hospitals as the AP cases during the study period and who did not have a diagnosis of AP in the current pregnancy. Maternal saliva was collected, plated, and stored with the use of the Oragene saliva cell collection kits (OGR500 and OGR250; DNA Genotek, Ottawa, Canada).
DNA extraction, genotyping, data quality control, and candidate gene/SNP selection Genomic DNA was extracted with the use of Qiagen DNAeasy system and manufacturer protocols (Qiagen, Valencia, CA). Genotyping to characterize genome-wide variation (>300,000 SNPs) was conducted with the use of the Illumina HumanCore-24 BeadChip platform (Illumina Inc, San Diego, CA). Genotype data quality control procedures were applied before data analyses. SNPs were excluded if they had excessive missing genotype (SNPs with genotype call rate of <95%), deviated from Hardy-Weinberg equilibrium (P<1e-05), and had low minor allele frequency (P<0.05). Individuals (n¼27) were excluded if they were duplicates or related (identity by decent value, >0.9), Figure 1) . The total number of 1597 individuals remained for further analysis (507 cases and 1090 control subjects). After the quality control step, SNP imputation was conducted to infer unobserved genotypes. The genotype data were phased with the use of Shape-IT 37 to infer haplotypes and improve imputation accuracy with the 1000 Genomes. Phased haplotypes were then used to impute our non-typed SNPs using IMPUTE2. 38 A total of 11 SNPs in 9 MB and OP genes (peroxisome proliferator-activated receptor gamma [ 16 were evaluated in the current analyses. The MB and OP genes were selected from previously published studies based on hypothesized functional and biologic significance and known associations with phenotypes that are related to placental function and/or perinatal outcomes in mammals. 16,28,39e43 Genetic risk score calculation
The wGRSs were calculated by multiplying the number of risk alleles for each MB and OP SNP by externally derived effect size estimates. It previously has been shown that the use of weights derived from the same data under analysis resulted in bias, compared with the use of externally derived estimated effect sizes as weights. 44 The corresponding externally derived effect sizes were obtained from the previously reported PAPE study, 16 a candidate gene study of AP. We assumed an additive genetic risk model, which corresponded to a linear increase of AP risk per unit increase in dosages of risk alleles (or the presence of 0, 1, and 2 risk alleles for directly typed SNPs). The weights (effect sizes) were multiplied by the number of respective risk alleles and summed across the SNPs to create a single score for each individual.
Statistical analyses
Mean and standard deviations for continuous variables and proportions for categoric variables were used to compare the characteristics of AP cases and control participants. Adjustment factors as confounders included in the models were principal components (the first 4 principal components represented population stratification), maternal age, infant sex, and a diagnosis of preeclampsia in the current pregnancy. The logistic regression models that included AP as the dependent variable, wGRS of SNPs in MB/OP genes as the independent variable, and adjustment factors were fit.
Participants were categorized into quartile groups defined by the 25th, 50th, and 75th percentile wGRS scores among control participants. The odds ratios (ORs) of AP and their corresponding 95% confidence intervals (CIs) and probability values were estimated from the logistic regression models. The corresponding ORs of each of the upper 3 wGRS quartiles were used to compare with the first quartile (<25th percentile) as the reference group. We assessed the test for linear trend across increasing quartiles of wGRS. The wGRS was also evaluated as a continuous variable to estimate the OR of AP per 1-unit increase in wGRS. In stratified analyses, multivariable adjusted logistic regression models were fit separately among groups defined by the diagnosis of preeclampsia in the current pregnancy, infant sex, and advanced maternal age (!35 vs 18e34 years). The likelihood ratio test was used to report effect modification. To determine statistical significance, P<.05 was used as a cut-off. Statistical analyses were performed with R software (version i386 3.1.2) and SAS software (version 13; SAS Institute Inc, Cary, NC).
Results
Sociodemographic and medical/obstetric characteristics of the study participants are shown in Table 2 . AP cases and control subjects were similar with respect to maternal age, education, marital status, employment, prepregnancy body mass index, planned pregnancy, infant sex, alcohol use, and vitamin use. Compared with control subjects, AP cases were more likely to deliver earlier (ie, shorter gestational age), deliver infants with lower birthweight, have a diagnosis of preeclampsia in the current pregnancy, and differ in population admixture captured by the first principal component.
Eleven previously reported SNPs in 9 MB and/or OP genes and corresponding effect size estimates were used to compute the wGRS for a total of 507 cases (median, 14.2; range, 7.9e19.0) and 1090 control subjects (median, 13.9; range, 7.5e18.5; Table 1 ). Compared with control subjects, the mean wGRS was higher for AP cases (14.1 [SD¼1.8] vs 13.7 [SD¼1.9]). In models that accounted for covariates (Table 3 and Supplementary Figure 2) , participants in the second quartile (25e50th wGRS percentile; score, 12.6e13.8) had a 1.45-fold (95% CI, 1.04e2.02; P¼.03) higher odds of AP compared with those in the lowest quartile (<25th wGRS percentile; score, <12.6). Participants in the third quartile (50e75th wGRS percentile; score, 13.9e15.0) had a 1.42-fold (95% CI, 1.02e1.98; P¼.04) higher odds of AP compared with those in the lowest percentile. Participants in the highest quartile(>75th wGRS percentile; score, >15.1) had a 1.75-fold (95% CI, 1.27e2.42; P¼7.0E-04) higher odds of AP compared with those in the lowest percentile. Significant linear trend in association between wGRS and AP risk was observed in this replication study (Pfor-trend¼.0003). When wGRS was entered in the model as a continuous predictor, the risk of AP was 1.12-fold (95% CI, 1.05e1.19; P¼3.0E-04) higher per 1-unit increase in wGRS.
In stratified analyses, among women with preeclampsia, the odds of AP were 3.92 (95% CI, 1.48, 10.36; p¼0.01), 3.50 (95% CI, 1.27, 9.65; p¼0.02), and 2.96 (95% CI, 1.15, 7.65; p¼0.02) for participants in the highest, third, and second wGRS quartiles, respectively, compared with participants in the lowest wGRS quartile (P-for-trend ¼0.03). The odds of AP was 1.27 (95% CI, 1.06-1.52; p¼0.01) per one-unit increase in wGRS among women with preeclampsia (Table 4 and Supplementary Figure 3 (Table 4 and Supplementary Figure 4) . Similarly, among participants with male infants, the odds of AP were 1.95 (95% CI, 1.24e3.07; P¼8.0E-04), 1.36 (95% CI, 0.78e2.00; P¼0.18), and 1.83 (95% CI, 1.16e2.87; P¼0.01), respectively, for women in the fourth, third, and second quartiles of wGRS compared with women in the reference group (lowest quartile; P-for-trend¼.004); corresponding odds ratios among participants with female infants were 1.37 (95% CI, 0.85e2.20; P¼.20), 1.47 (95% CI, 0.91e2.39; P¼.11), and 1.11 (95% CI, 0.68e1.81; P¼.67; P-for-trend¼.35; Pfor-interaction¼.44). Women who carried a male infant had a 1.14-fold (95% CI, 1.05e1.24; P¼.002) higher odds of AP per 1-unit increase in wGRS. Women who carried a female infant had a 1.09-fold (95% CI, 1.00e1.19; P¼.06) higher odds of AP per 1-unit increase in wGRS (Table 4 and Supplementary Figure 5 ).
Comment
Principal findings
In this candidate gene association study of AP, we provide strong evidence that genetic variants in MB (CAMK2B, ajog.org P¼3.0E-04) higher odds of AP per 1-unit increase in wGRS. We also observed evidence suggestive of possible effect modification (P-for-interaction¼.12) of the association between MB/OP wGRS and risk of AP by preeclampsia. Women who had preeclampsia and were in the highest quartiles for MB/OP wGRS had a 3.92-fold higher odds of AP (95% CI, 1.48e10.36; P¼.01) compared with women who had preeclampsia and were in the lowest quartile for MB/OP wGRS. Preeclamptic women also had a 1.27-fold (95% CI, 1.06e1.52; P¼0.01) higher odds of AP per 1-unit increase in wGRS.
Research in context of other results
Our candidate gene association study allowed investigation of genetic variants that may not account individually for large effects in complex traits when assessed with the use of an underpowered genome-wide association study, which provides a more effective and economical hypothesis-driven method to assess the role of genetic variations. 45 Other previous candidate gene association studies of AP included investigations of genes in thrombophilia, rennin-angiotensin system, folate metabolism, and interleukin 1 receptor antagonisterelated and oxidative stress pathways. 11,12,46e48 However, these studies were small in sample size that showed modest effects and did not validate the findings with the use of either SNPs or genetic risk scores in an independent study. Using SNPs in MB/OP genes and wGRS analysis, our team previously reported that participants (470 AP cases and 473 control subjects) in the highest quartiles of the risk score (!10.0) had 1.9-fold (95% CI, 1.2e3.1) higher odds of AP ( 8.0) compared with participants in the lowest risk score group. 16 Using SNPs in 31 This study was also limited in sample size, but it allowed for other mechanistic investigations such as effects of imprinting on AP. Placental growth and development, which are key underlying pathways that may later lead to the occurrence of AP, may be under the control of fetal genes that are inherited from the father. 5, 49 In the current study, we were able to replicate the associations of maternal MB/OP wGRS that we reported before with risk of AP. This independent replication study will minimize concerns of failure to replicate, which is a recurring problem with candidate gene association studies. 45, 50, 51 Clinical implications MB and OP genes that were evaluated in our study have been known to influence phenotypes that are related to placental function and/or perinatal outcomes. For instance, protein kinase C-alpha (PRKCA), which is an MB gene among family of serine-and threonine-specific protein kinases that can be activated by calcium and the second messenger diacylglycerol, is critical in many cellular processes that include cell signaling through phosphorylation of variety of proteins. 52 A body of literature suggests PRKCA affects contractility 53 in cardiac myocytes, 54, 55 vascular, 56 and myometrial cells, 57, 58 whose abnormal mechanisms can trigger AP. 59 Peroxisome proliferator-activated receptor gamma (PPARG), which is a master regulator of MB and highly expressed in the placenta, mediates defective placentation (eg, inhibition of trophoblast invasion) through oxidized low-density lipoproteins in cytotrophoblasts of villous and extravillous cells, which are involved in uterus invasion. 23, 60 Defective invasion of the uterine spiral arteries is involved directly in preeclampsia, 60 which is a common risk factor of AP. 32 Trophoblast dysfunction because of the failure of spiral artery physiologic transformation in the placental basal plate may be responsible for AP. 61 Therapeutic efforts to reduce the risk of AP can be enhanced by improved biologic understanding of these maternal MB/OP pathways and the identification of women who would be at high risk for AP.
Research implications
Genetic risk scores for the prediction of risk are particularly advantageous because they summarize risk-associated variation across the genome, and they are robust to issues of imperfect linkage and relatively uncommon individual risk alleles for a single SNP. 62, 63 In the current study, we identified and evaluated the same SNPs and used the previously reported estimated effect sizes. Interestingly, we found stronger a trend in association between wGRS and higher odds of AP in the current study (P-fortrend ¼.0003) compared with the previous report (P-for-trend¼.01), because of the larger sample size in the current study.
Our stratified wGRS-AP analyses findings may allow the identification of subgroups in the population who are more susceptible to the deleterious effects of genetic risk factors. 64 This approach has been suggested when standard univariate tests (ie, evaluation of each SNP for interaction independently) fail to identify any interactions. 65 We found suggestive evidence that support higher AP risk conferred by MB/OP genetic variants among women with preeclampsia, and vice versa. Although, the global test for interaction between wGRS and preeclampsia was not significant, among women with preeclampsia, the odds of AP were higher for successively increasing quartiles of wGRS, compared with normotensive women in the lowest quartile of wGRS. A systematic review showed that patients with preeclampsia had 1.73-fold (95% CI, 1.47e2.04) increased odds of AP compared with normotensive patients. 66 Maternal and fetal genetic factors contribute to 35% and 20% of the variance in preeclampsia, respectively. 67 Reduced placental perfusion is thought to interact with preexisting maternal factors such as hypertension, renal disease, obesity, gestational diabetes mellitus, insulin resistance, and lipid abnormalities, 68 which contribute to susceptibility to preeclampsia. 68 As a result, the observed potential interaction in our study may be a reflection of potential gene-environment interaction and warrants further investigation of the roles of MB/OP genes in preeclampsia.
Strengths and limitations
Our study is the largest candidate gene study of AP that has the potential to enhance our understanding of genetic variations in maternal genome that contribute to a multifactorial heritable disorder such as AP. A key strength of our study is that we replicated the association of a wGRS of MB/OP with AP in an independent dataset. We studied Peruvians, which is a population with high prevalence of pregnancy complications, including AP. However, limitations of our study include potential misclassification of subclinical AP, which may introduce bias in the interpretation of our study results or reduce power of our study. Comparing severe AP with mild abruption and/or nonabruption cases may minimize this limitation and facilitate epidemiologic and genetic research. 36 Our study evaluated genetic variations of the mother. Future studies should also investigate genetic variations in the fetus and of the placenta, where abnormal vasculature, thrombosis, lesions, and reduced perfusion all culminate in the eventual occurrence of AP. In addition, findings from our study population may not be generalizable to other populations that differ in genetic and other characteristics, such as smoking.
Conclusion
In summary, findings reported herein provide strong evidence for DNA variants that encode for genes involved in the MB and OP pathways, conferring risk for AP. Future studies that will examine whether the identified variants contribute to AP risk in other populations are warranted. Similar genetic studies that will involve MB and OP, or other potential pathways underlying AP, can inform preventative and therapeutic
Original Research OBSTETRICS ajog.org efforts to reduce risk of AP. In addition, they could facilitate identification of individuals who have an elevated risk for AP, which is a significant public health problem. n
Preeclampsia status
Odds ratios and 95% confidence intervals for abruptio placentae risk in relation to quartiles of weighted genetic risk scores were computed from selected mitochondrial biogenesis and/or oxidative phosphorylation single nucleotide polymorphisms according to preeclampsia status. The lowest quartiles served as the reference group.
Q, quartile; wGRS, weighted genetic risk score. 
Maternal age status
Odd ratios and 95% confidence intervals for abruptio placentae risk in relation to quartiles of weighted genetic risk scores were computed from selected mitochondrial biogenesis and/or oxidative phosphorylation single nucleotide polymorphisms according to maternal age status. The lowest quartiles served as the reference group.
Infant sex status
Odds ratios and 95% confidence intervals for abruptio placentae risk in relation to quartiles of weighted-genetic risk scores were computed from selected mitochondrial biogenesis and/or oxidative phosphorylation single nucleotide polymorphisms according to infant sex status. The lowest quartiles served as the reference group.
Q, quartile; wGRS, weighted genetic risk score. ajog.org
